A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, MULTICENTER, DOSE-RANGING, STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-04965842 IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Abrocitinib (Primary)
- Indications Atopic dermatitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Pfizer
- 12 Nov 2023 Results of post hoc pooled analysis from phase 2b (NCT02780167) and phase 3 (NCT03349060, NCT03575871) monotherapy trials assessing the efficacy and safety of abrocitinib in patients with atopic dermatitis and allergic comorbidities, published in the Allergy.
- 08 Nov 2023 Results of pooled post hoc NCT02780167, NCT03349060, NCT03575871 assessing efficacy and safety of abrocitinib based on patient race, ethnicity, and Fitzpatrick skin type published in the Annals of Allergy, Asthma and Immunology
- 07 Aug 2022 Results of post hoc analysis evaluating maintenance of disease control during a 4-week drug-free follow-up period in patients with moderate-to-severe AD, published in the Dermatology and Therapy